Heated chemo during surgery shows promise for tough ovarian cancer

NCT ID NCT05123807

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining surgery to remove visible tumor with heated chemotherapy delivered directly into the abdomen can help women whose mucinous ovarian cancer has returned. About 30 participants will receive this intensive treatment. The goal is to see how long they live without the cancer growing again and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hyperthermic intraperitoneal chemotherapy (HIPEC)
What this could lead to: If successful, this approach could offer a new treatment option to control recurrent mucinous ovarian cancer and potentially extend survival.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The combination of major surgery and heated chemotherapy carries risks like infection, organ damage, and complications from anesthesia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mucinous ovarian cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.